Puma Biotechnology, Inc.

Puma Biotechnology, Inc.

Puma Biotechnology, Inc.

Overview
Date Founded

2010

Headquarters

10880 WILSHIRE BOULEVARD,, SUITE 2150, LOS ANGELES, CA, 90024

Type of Company

Public

Employees (Worldwide)

269

Industries

Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Contact Data
Trying to get in touch with decision makers at Puma Biotechnology, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Financial Officer

Chief Commercial Officer

Chief Medical & Scientific Officer

Senior Vice President, Regulatory Affairs, Medical Writing & Project Management

Owner Partner

Owner

Board of Directors

Founder at Puma Biotechnology, Inc.

Chief Financial Officer at Sera Prognostics, Inc.

Co-Founder at Kura Oncology, Inc.

Former Senior Medical Director-Oncology Division at AstraZeneca Plc

Former Vice President, Urology Business Unit at ALZA Corp.

Former Vice President, Marketing at Sanofi

Chief Executive Officer & Director at Verastem, Inc.

Former President, Chief Executive Officer & Director at BioNTech US, Inc.

Paths to Puma Biotechnology, Inc.
Potential Connections via
Relationship Science
You
Puma Biotechnology, Inc.
Owners & Shareholders
Details Hidden

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment and philanthropy—all toward the end goal of cures for disease, improved quality of life and reduced cost of care. As of late 2019, the firm manages nearly $10 billion in assets. Providing value beyond capital, Deerfield generally maintains a combined portfolio of more than 200 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company. Having many years of operational expertise, Deerfielders are highly engaged and adept at navigating the complex crosscurrents ever-present in the healthcare and financial industries. Collaboration, intellectual curiosity and pragmatism drive Deerfield’s approach. With its holistic view, Deerfield tailors flexible financing options designed to meet the needs of entrepreneurs and corporate partners.

Details Hidden

Camber Capital Management seeks to generate capital appreciation without regard to current income by investing primarily in publicly-traded common stocks of healthcare companies across a variety of industries including healthcare services and facilities, pharmaceuticals, medical products and devices and biotechnology. Although most of their investments are within the healthcare industry, the firm may occasionally invest in other sectors if more attractive opportunities are identified. Camber Capital Management employs a fundamental, bottom-up research approach designed to identify high-quality companies whose inherent value is not adequately reflected in a company's market valuation.

Details Hidden

Weatherbie Capital employs a fundamental, bottom-up research approach to investing in growth equities. They aim to identify and invest in attractive US small- and mid-cap companies poised for growth. All portfolio managers/analysts are generalists, with coverage across several sectors. Each portfolio manager/analyst has primary responsibility over two to three major growth sectors from which to research companies of potential investment interest. Each member of the investment team is responsible for buy and sells decisions. If a company falls short of our expectations for any non-trivial reason, the firm will sell that stock.

Recent Transactions
Details Hidden

Puma Biotechnology, Inc. issued USD Common Stock

Details Hidden

Puma Biotechnology, Inc. issued USD Common Stock

Details Hidden

Puma Biotechnology, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Underwriter

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Auditor

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Underwriter

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Managing Director

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Underwriter

Advised onPuma Biotechnology, Inc. issued USD Common Stock

Clients

CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise. The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioural health, medical management capabilities. The Corporate segment involves in providing management and administrative services. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Cigna Corp. is a global health service company, which is dedicated to improving the health, well-being and peace of mind. Its products and services include an integrated suite of health services such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits and other related products including group life, accident and disability insurance.

Cigna is a global health service company, dedicated to helping the people we serve improve their health, well-being and sense of security. We make this happen through a broad range of integrated health care and related plans and services, and proven health and well-being programs that are targeted to the unique needs of our customers, clients and partners. "At Cigna, we understand that people are unique, and so, too, is their health. In a world of many millions, we see each person defining a healthy life on his or her own terms. It's our aim to be part of that journey, helping people achieve better health and peace of mind along the way." - David Cordani, CEO

Key Stats and Financials As of 2019
Market Capitalization
$458M
Total Enterprise Value
$339M
Earnings Per Share
$-1.95
Revenue
$272M
Net Profit
$-75.6M
EBITDA
$-31M
EBITDAMargin
-11.39%
Total Debt
$120M
Total Equity
$17.5M
Enterprise Value / Sales
1.25x
TEVNet Income
-4.48x
Debt TEV
0.35x
Non-Profit Donations & Grants
Investors
Details Hidden

Fidelity Investments Canada offer Canadian investors a full range of domestic, international and income-oriented mutual funds, as well as asset allocation, managed solutions, ETFs and a high net-worth program. It also invests in real estate. The firm employs fundamental analysis with a bottom-up stock picking approach to select investments. Their portfolio managers and analysts employ a hands-on investment approach which includes visiting companies, conducting interviews and communicating with competitors. Fidelity Investments Canada covers over 90% of the companies included on the major global indices.

Details Hidden

Wellington Management Co. LLP (Private Equity) focuses in companies located in US. The firm invests in consumer discretionary, technology, financial services, biotech, and health care. They provide capital for growth and later stage capital requirement.

Details Hidden

Orbimed Advisors Private Equity seeks investment opportunities in private and public healthcare companies located in globally primarily North America, Asia, Europe and Israel. The firm targets companies operating in the fields of biopharmaceutical, medical device, diagnostics and healthcare services. It provides financing for seed stage capital for large publicly traded companies.

Suppliers
Pfizer, Inc. Medical Support Services | New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

CaligorRx, Inc. Medical Products & Equipment | Secaucus, NJ

Caligor RX, Inc. provides clinical trial supply and logistics services. It manages the regulatory, logistics, and supply chain challenges of sourcing, storing, and distributing investigational drugs for comparator clinical trials and unlicensed medicines for expanded access programs. The firm serves pharmaceutical and biotechnology companies. The company is headquartered in Secaucus, NJ.

Competitors
Seagen Inc. Pharmaceuticals - Bothell, WA

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Novartis AG Pharmaceuticals - Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Puma Biotechnology, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Puma Biotechnology, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Puma Biotechnology, Inc..